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Swine are often asymptomatic carriers of Salmonella spp., and interventions are needed
to limit colonization of swine to enhance food safety and reduce environmental contam-
ination. We evaluated the attenuation and potential vaccine use in pigs of a Salmonella
enterica serovar Typhimurium mutant of rfaH, the gene encoding the RfaH antiterminator
that prevents premature termination of long mRNA transcripts. Pigs inoculated with wild-
type S.Typhimurium exhibited a significant elevation in average body temperature (fever) at
1 and 2 days post-inoculation; rfaH -inoculated pigs did not (n=5/group). During the 7-day
trial, a significant reduction of Salmonella in the feces, tonsils, and cecum were observed
in the rfaH -inoculated pigs compared to wild-type inoculated pigs. To determine whether
vaccination with the rfaH mutant could provide protection against wild-type S.Typhimurium
challenge, two groups of pigs (n=14/group) were intranasally inoculated with either the
rfaH mutant or a PBS placebo at 6 and 8 weeks of age and challenged with the parental,
wild-type S. Typhimurium at 11 weeks of age. The average body temperature was signifi-
cantly elevated in the mock-vaccinated pigs at 1 and 2 days post-challenge, but not in the
rfaH -vaccinated pigs. Fecal shedding at 2 and 3 days post-challenge and colonization of
intestinal tract tissues at 7 days post-challenge by wild-type S. Typhimurium was signifi-
cantly reduced in the rfaH -vaccinated pigs compared to mock-vaccinated pigs. Serological
analysis using the IDEXX HerdChek Swine Salmonella Test Kit indicated that vaccination
with the rfaH mutant did not stimulate an immune response against LPS.These results indi-
cate that vaccination of swine with the attenuated rfaH mutant confers protection against
challenge with virulent S.Typhimurium but does not interfere with herd level monitoring for
Salmonella spp., thereby allowing for differentiation of infected from vaccinated animals
(DIVA).
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INTRODUCTION
An estimated one million cases of foodborne illness are attributed
to non-typhoidal Salmonella spp. each year in the U.S. at a pre-
dicted cost of $2.3 billion (1, 2). Non-typhoidal Salmonella spp.
are a leading cause of hospitalization (35%) and death (28%) in
the U.S. due to foodborne disease (2). Of 14 foodborne pathogens
that cause 95% of foodborne illnesses, hospitalizations, and death
in the U.S., non-typhoidal Salmonella spp. are the leading cause
of disease burden (27%) measured by quality-adjusted life years
(QALYs) (3).
Most of the >2,400 Salmonella serovars are ubiquitous in the
environment and many can colonize food producing animals and
poultry as well as wild animals and birds without causing overt
disease. In the U.S., ~68,000 cases of pork-associated, human
salmonellosis occur each year with an estimated social cost of $218
million annually (4). Of 104 pathogen–food combinations, the
annual disease burden due to S. enterica in pork is estimated as the
13th highest. The most recent study from the USDA’s National Ani-
mal Health Monitoring System, Swine 2006, reported that 52.6%
of swine production sites (representing 94% of the U.S. swine
inventory) were positive for Salmonella spp. (5). Swine that are
Salmonella carriers are a food safety risk for consumers of pork, an
animal health risk to non-colonized/uninfected pigs, an econom-
ical risk to producers due to reduced feed conversion/efficiency
(6, 7), and an environmental risk due to fecal shedding of the
pathogen into swine manure that is used as a soil amendment.
Interventions are needed to limit the colonization of swine with
Salmonella spp. and reduce the risks to public health, animal
health, and the environment.
The potential use of a Salmonella enterica serovar
Typhimurium rfaH mutant as a vaccine candidate has been
described (8, 9). The RfaH antiterminator prevents the premature
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termination of long mRNA transcripts encoded by large oper-
ons. A 5′ cis-acting operon polarity suppressor (ops) element
is required to enhance transcription elongation from operons
in the RfaH regulon (10, 11). S. Typhimurium rfaH mutants
have decreased transcription of genes encoding lipopolysaccharide
(LPS) core, O-antigen, Salmonella Pathogenicity Island 4 (SPI-4),
flagellum/chemotaxis, and type III secretion system 1 (T3SS-1)
(12). However, the decreased transcription of some of these oper-
ons may be due indirectly to the loss of LPS. A S. Typhimurium
SL1344 rfaH mutant is attenuated for virulence (both oral and
intraperitoneal inoculation) in the BALB/c mouse model of sys-
temic disease compared to wild-type SL1344 (8). Immunization of
BALB/c mice with three doses of an rfaH mutant [5× 107 colony
forming units (CFU)] at 2-week intervals was protective against
challenge with 5× 107 CFU of wild-type SL1344 at 2 weeks fol-
lowing the final vaccine dose (0/4 vs. 4/4 deaths for vaccinated
and naïve mice). Further investigation indicated that vaccination
of BALB/c mice with three increasing doses (2× 107, 2× 108,
and 2× 109 CFU) of the SL1344 rfaH mutant at 2-week inter-
vals resulted in significant protection against homologous (86%)
and heterologous (40%) challenge with 5× 106 CFU of either
wild-type SL1344 or wild-type S. Enteritidis NCTC13349, respec-
tively (13). These results indicate that vaccination of mice with
the SL1344 rfaH mutant provides some cross-protection against
other serovars in addition to S. Typhimurium.
In the current study, an rfaH knockout mutant of Salmo-
nella enterica serovar Typhimurium was constructed to determine
whether: (1) the strain was attenuated in pigs, (2) would pro-
tect swine against virulent S. Typhimurium challenge, while (3)
allowing for DIVA using the IDEXX HerdChek Swine Salmonella
Test Kit. This is the first report of an rfaH mutant evaluation
in swine and our results indicate that rfaH -vaccinated pigs have
reduced disease severity, pathogen fecal shedding, and intestinal
colonization due to virulent S. Typhimurium challenge, but swine
vaccination did not interfere with the herd level monitoring system
for Salmonella spp.
MATERIALS AND METHODS
STRAIN CONSTRUCTION AND GROWTH CONDITIONS
The S. Typhimurium BBS 202 (rfaH :neo) strain was constructed
by recombineering as previously described (14). Briefly, oligos
oBBI 189 (atgcaatcctggtatttactgtactgcaaacgcgggcaacttcagcatagag
cagtgacgtagtcgc) and oBBI 190 (ctaaatcttgcgaaaaccggtgttttttacgct
ctgcttcacttcgatagctgaatgagtgacgtgc) were used to PCR amplify the
oBBI 92/93-neo template for synthesis of a linear knockout frag-
ment. The 5′ end (bold) of oBBI 189 and oBBI 190 have homology
to the 5′ and 3′ rfaH target sequences (respectively) whereas the
3′ end (underlined) of the oligos have homology to oBBI 92/93-
neo encoding an antibiotic resistance gene flanked by universal
sequences that truncate potential translation of the target gene.
Following PCR amplification, gel electrophoresis was performed
using a 1% agarose gel in TBE and the oBBI 189/190-neo knock-
out fragment was gel purified using a BioRad Freeze ‘N Squeeze
column (Hercules, CA, USA). The linear knockout fragment con-
taining the neo gene was electroporated into arabinose-induced
competent cells of S. Typhimurium BSX 7 (14) containing the
plasmid pKD46 encoding Lambda exo, bet, and gam to facilitate
recombination of the DNA fragment (15). Kanamycin-resistant
transformants were screened by PCR to confirm the replacement
of rfaH with the neo gene and this strain was stocked as BBS 195.
Due to the rfaH mutant being a poor recipient for P22 bind-
ing, the rfaH gene was cloned into a plasmid to complement the
rfaH mutation using primers oBBI 193 (caggaagacgcgttaaatcg)
and oBBI 194 (gaacgatcgctaaatcttgc). The oBBI 193 primer binds
within yigC (STM3978), ~625 bp upstream of the codon for the
rfaH start methionine. The binding site for the oBBI 194 primer
overlaps with the rfaH stop codon. Primers oBBI 193 and oBBI 194
were used to amplify the rfaH region from the S. Typhimurium
χ4232 genome, and the PCR product was cloned using the pBAD
TOPO TA Expression Kit (Invitrogen, Carlsbad, CA, USA) fol-
lowed by transformation into One Shot TOP10 competent E. coli.
The pBAD-oBBI193/194 plasmid was extracted from the TOP10
strain and transformed into BBS 195 (rfaH :neo), single colony iso-
lated, and stocked as BBS 201. Using a P22 high-transducing phage
lysate grown on BBS 201, the rfaH :neo mutation was transferred
to wild-type S. Typhimurium χ4232, creating BBS 202.
The S. Typhimurium strainsχ4232 and BBS 202 were grown in
LB in the presence of nalidixic acid without and with kanamycin,
respectively. Antibiotics were used at the following concentrations:
ampicillin (100µg/ml) for pKD46, kanamycin (50µg/ml), and
nalidixic acid (30µg/ml).
ETHICS STATEMENT
All experimental procedures involving animals were in compliance
with the recommended principles described in the Guide for the
Care and Use of Laboratory Animals by the National Research
Council of the National Academies and were approved by the
USDA-ARS, National Animal Disease Center, Animal Care, and
Use Committee.
ANIMAL TRIAL #1
Ten crossbred, conventionally raised piglets from five Salmo-
nella-fecal-negative sows were weaned at 12 days of age and
shipped to the National Animal Disease Center, Ames, IA, USA.
Siblings from each litter were divided and raised in two isola-
tion rooms (n= 5/room). Piglets tested fecal-negative for Sal-
monella spp. thrice over a 4-week period using bacteriological
culture with selective enrichment (16). At 6 weeks of age (day
zero), pigs received an intranasal inoculation of 1 ml PBS con-
taining either 1× 109 CFU of BBS 202 (rfaH :neo; n= 5) or S.
Typhimurium χ4232 (wild-type; n= 5). Clinical symptoms and
pathogen fecal shedding were monitored at 0, 1, 2, 3, 5, and 7 days
post-inoculation (dpi) (see below).
ANIMAL TRIAL #2
Twenty-eight crossbred, conventionally raised piglets from four
Salmonella-fecal-negative sows were weaned at 12 days of age
and shipped to the National Animal Disease Center, Ames, IA,
USA. Equally divided from each litter, the pigs were raised in
two isolation rooms (n= 14/room) and tested fecal-negative for
Salmonella spp. twice over a 4-week period using bacteriological
culture with selective enrichment. At 6 weeks of age, pigs received a
1 ml intranasal inoculation of either 1× 109 BBS 202 or a placebo
(PBS); a booster inoculation occurred 2 weeks later at 8 weeks
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of age. At 11 weeks of age, all pigs were intranasally challenged
with PBS containing 1× 108 CFU of wild-type S. Typhimurium
(χ4232) and monitored for clinical disease symptoms,Salmonella-
fecal shedding and intestinal colonization over a 7-day period (see
below).
SAMPLE COLLECTION AND PROCESSING
Swine body temperatures were determined using a rectal ther-
mometer, and blood samples were obtained via the jugular vein
at each inoculation time point as well as 7 days post-challenge.
Fecal samples were obtained for quantitative and qualitative Sal-
monella culture analysis as previously described (16) with the
addition of XLT-4 medium containing the appropriate antibiotics
to select for each strain (nalidixic acid for χ4232; nalidixic acid
and kanamycin for BBS 202). At 7 dpi, all pigs were euthanized
and necropsies performed to obtain tissue samples from the ton-
sil and the intestinal tract (ileal Peyer’s Patches, ileocecal lymph
nodes, and cecum) for quantitative and qualitative Salmonella cul-
ture analysis as previously described with slight modification (17).
One hundred microliters of each homogenized tissue (1 g of tissue
combined with 2 ml of PBS) was aliquoted onto BGS and XLT-4
media containing kanamycin and/or nalidixic acid (see below).
To differentiate between the wild-type and rfaH mutant strains
in the bacteriological culture assays, fecal and tissues samples were
plated on medium containing nalidixic acid alone and medium
containing both nalidixic acid and kanamycin. As bothχ4232 and
BBS 202 are resistant to nalidixic acid, the medium with nalidixic
acid and kanamycin was used to identify BBS 202. Subtraction
of the number of colonies present on the kanamycin–nalidixic
acid medium from the colonies present on the nalidixic acid only
medium determined the number of χ4232 colonies.
All statistical analyses were performed in GraphPad Prism 5.01
(GraphPad Software, Inc., La Jolla, CA, USA). Statistical analysis of
body temperatures for each treatment group was performed using
repeated measures ANOVA followed by Bonferroni’s Multiple
Comparison Test. Statistical analysis of Salmonella present (Log10
colony forming units per gram) in fecal samples was analyzed
by two-way ANOVA followed by Bonferroni post-tests. Statistical
analysis of Salmonella present (Log10 colony forming units per
gram) in tissues at 7 dpi was analyzed using the Two Sample t -test
for the Means.
FECAL SCORE ANALYSIS
Each fecal sample in animal trial #2 was assigned a diarrhea score
(18) by the same four evaluators at the time of collection (prior
to information concerning shedding status) using a scale of 1–
5 (1= dry feces, 2=moist feces, 3=mild diarrhea, 4= severe
diarrhea, and 5=watery diarrhea). Statistical analysis of diarrhea
scores was analyzed by two-way ANOVA followed by Bonferroni
post-tests.
IDEXX HerdChek SWINE SALMONELLA ANTIBODY ASSAY
Serum antibody analysis to LPS antigen derived from Salmo-
nella serogroups B, C1, and D was performed using the IDEXX
HerdChek Swine Salmonella Test Kit (IDEXX Europe B.V., Hoofd-
dorp, Netherlands). The assay and interpretation were performed
per the manufacturer’s instructions. Briefly, the 30-min incuba-
tion was performed and the sample to positive (S/P) ratio was
calculated for each sample using S/P= (sample mean− negative
control mean)/positive control mean− negative control mean). A
sample’s S/P ratio of ≥0.25 was considered positive and <0.25
was considered negative. Analysis of piglet serum was performed
in-house whereas sow screening was performed by Boehringer
Ingelheim, Vetmedica, Inc. (Ames, IA, USA).
RESULTS AND DISCUSSION
rfaH MUTANT OF S. TYPHIMURIUM IS ATTENUATED IN SWINE
An rfaH mutant of S. Typhimurium was constructed and tested for
attenuation in vivo. Following a 1× 109 CFU inoculation, the aver-
age body temperature (fever) of pigs inoculated with the parental,
wild-type S. Typhimurium χ4232 was significantly higher at day
1 (39.9°C) and day 2 (39.3°C) post-inoculation compared to day
0 (38.2°C) for the wild-type strain (Figure 1A; P< 0.05). Also,
the average body temperature of pigs inoculated with wild-type S.
Typhimurium was significantly higher at 1 dpi compared to pigs
inoculated with the rfaH mutant (Figure 1A; 39.9°C vs. 38.5°C;
P< 0.05). In fact, the average body temperature of the pigs inocu-
lated with the rfaH mutant did not significantly increase through-
out the 7-day trial. Swine fecal shedding of the S. Typhimurium
rfaH mutant was significantly reduced (up to 2.5 logs) at days 3,
5, and 7 dpi compared to wild-type S. Typhimurium (Figure 1B;
P< 0.05). Furthermore, tissue colonization was significantly lower
in the tonsil (>2 logs) and cecum (2.5 logs) in the pigs inoculated
with the rfaH mutant compared to wild-type S. Typhimurium
(Figure 1C; P< 0.05), although no difference in colonization of
the ileal Peyer’s Patches or ileocecal lymph nodes occurred. Thus,
the rfaH mutant is attenuated for clinical symptoms (fever) with
reduced fecal shedding and tissue colonization compared to the
parental, wild-type S. Typhimurium.
VACCINATION OF PIGS WITH THE rfaH MUTANT SIGNIFICANTLY
REDUCES THE EFFECTS OF SUBSEQUENT CHALLENGE WITH
WILD-TYPE S. TYPHIMURIUM
To determine whether vaccination with the rfaH mutant could
provide protection against virulent S. Typhimurium challenge in
swine, pigs were inoculated with the potential vaccine strain at
6 weeks of age and boosted 2 weeks later. As similarly reported
in the attenuation trial above, no significant increase in aver-
age body temperature was observed following vaccination or
booster vaccination of the pigs, thereby corroborating the data
presented in Figure 1A for the rfaH mutant (data not shown).
Mock-vaccinated pigs (n= 14) and rfaH -vaccinated pigs (n= 14)
were challenged with 1× 108 CFU of the parental, wild-type S.
Typhimurium at 11 weeks of age. The swine rectal temperature
increased significantly at days 1 (40.3°C) and 2 (40.1°C) post-
challenge compared to day 0 (39.1°C) in the mock-vaccinated pigs
(Figure 2A; P< 0.05). Moreover, the swine rectal temperature was
significantly increased in mock-vaccinated pigs compared to rfaH -
vaccinated pigs at days 1 (40.3°C vs. 39.4°C) and 2 (40.1°C vs.
39.3°C) post-challenge (Figure 2A; P< 0.05). Following challenge
with wild-type S. Typhimurium, the average body temperature
of the pigs vaccinated with the rfaH mutant did not significantly
increase throughout the 7-day trial. The average diarrhea score,
a subjective measurement of moisture content, was significantly
higher in mock-vaccinated pigs compared to rfaH -vaccinated pigs
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FIGURE 1 | Average rectal temperature, fecal shedding, and tissue
colonization were significantly reduced in pigs inoculated with the
rfaH mutant compared to the parental wild-type S.Typhimurium. At
6 weeks of age, swine were inoculated with 1 ml of PBS containing either
1×109 colony forming units (CFU) of BBS 202 (rfaH :neo; n=5) or S.
Typhimurium χ4232 (wild-type; n=5). (A) Swine rectal temperature at 0, 1,
2, 3, 5, and 7 dpi. (B) Salmonella bacteriological analysis (colony forming
units per gram) of swine fecal samples obtained at 1, 2, 3, 5, and 7 dpi. (C)
Salmonella bacteriological analysis (colony forming units per gram) of the
tonsil, ileocecal lymph nodes (ICLN), Peyer’s Patches, and cecum obtained
during necropsy at 7 dpi. *Significant difference (P<0.05) between swine
inoculated with wild-type S.Typhimurium compared to the rfaH mutant at
the indicated time point. #Significant difference (P< 0.05) in wild-type
inoculated pigs at the indicated time point compared to day 0.
at 2 dpi (2.7 vs. 2.1, respectively; P< 0.05). Swine fecal shed-
ding of S. Typhimurium was significantly increased (~1.5 logs)
at days 2 and 3 post-challenge in mock-vaccinated pigs compared
to rfaH -vaccinated pigs (Figure 2B; P< 0.05). Furthermore, S.
Typhimurium colonization was significantly decreased in the ileo-
cecal lymph nodes, ileal Peyer’s Patches, and cecum (~10-fold)
at 7 days post-challenge in rfaH -vaccinated pigs compared to
FIGURE 2 |The rfaH -vaccinated pigs had significantly lower average
rectal temperature, fecal shedding, and tissue colonization compared
to the mock-vaccinated pigs following challenge with wild-type S.
Typhimurium. At 6 and 8 weeks of age, pigs were inoculated with the
potential rfaH vaccine strain (BBS 202) or mock–vaccinated with PBS
(n=14/group). At 11 weeks of age, all 28 pigs were challenged with
1×108 CFU of the parental, wild-type S.Typhimurium χ4232. (A) Swine
rectal temperature at 0, 1, 2, 3, and 7 days post-challenge. (B) Salmonella
bacteriological analysis (colony forming units per gram) of swine fecal
samples obtained at 1, 2, 3, and 7 days post-challenge. (C) Salmonella
bacteriological analysis (colony forming units per gram) of the tonsil,
ileocecal lymph nodes (ICLN), Peyer’s Patches, and cecum obtained during
necropsy at 7 dpi. *Significant difference (P<0.05) comparing
rfaH -vaccinated to mock-vaccinated pigs at the same time point.
#Significant difference (P< 0.05) in mock-vaccinated pigs at the indicated
time point compared to day 0.
mock-vaccinated pigs (Figure 2C; P< 0.05). Hence, vaccination
with the rfaH mutant reduced clinical symptoms (fever and diar-
rhea), Salmonella-fecal shedding and intestinal colonization upon
challenge with virulent S. Typhimurium.
rfaH MUTANT IS A DIVA VACCINE
To determine if the pigs vaccinated with the rfaH mutant were
producing detectable antibodies to Salmonella LPS antigen, sera
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FIGURE 3 | Serum from rfaH -vaccinated swine is negative in the IDEXX
HerdChek Swine SalmonellaTest Kit 5-weeks after initial vaccination.
The number of pigs with serum containing antibodies to Salmonella LPS at
6-weeks (initial vaccination), 8-weeks (booster vaccination), 11-weeks
(challenge), and 12-weeks (7 days post-challenge) of age. The number of
positive pigs at each time point are shown. All pigs were challenged with
wild-type S.Typhimurium at 11-weeks of age. A sample’s S/P ratio of ≥0.25
was considered positive and <0.25 was considered negative.
from all 28 pigs (14 mock-vaccinated and 14 rfaH -vaccinated)
were assayed using the IDEXX HerdChek Swine Salmonella Test
Kit at multiple time points including 11-weeks of age (5 weeks
following initial inoculation with the rfaH mutant and the day of
wild-type S. Typhimurium challenge). All 28 pigs were negative
for antibodies to Salmonella LPS antigen by ELISA at 11-weeks
of age, indicating that vaccination with the S. Typhimurium rfaH
mutant did not stimulate the production of antibodies against
LPS (Figure 3). Therefore, the rfaH vaccine strain could be used
in conjunction with Salmonella surveillance programs in swine for
DIVA. At 12-weeks of age (7-days post-challenge with wild-type
S. Typhimurium), the sera from 85% of rfaH -vaccinated and 78%
of mock-vaccinated pigs were positive in the LPS ELISA assay, sig-
nifying that seroconversion to Salmonella LPS antigen following
wild-type S. Typhimurium challenge had occurred. These results
indicate that vaccination of swine with the rfaH DIVA vaccine
does not interfere with the detection of a subsequent exposure to
Salmonella.
At 6-weeks of age, 8 of 28 piglets (4 pigs in each of the two
treatment groups) were positive for antibodies to Salmonella LPS
antigen by ELISA (Figure 3). These eight piglets were siblings from
the same sow and their antibodies waned as the age of the piglets
increased. Taken together, these data indicate that the antibod-
ies to Salmonella LPS in these piglets were maternal antibodies.
Salmonella surveillance data including Swine 2006 suggests that
Salmonella colonization in swine herds is not unusual. From 2011
to 2013, we screened 112 sows from 4 commercial swine facilities
for the presence of Salmonella spp. in feces and antibodies to Sal-
monella LPS in serum. Salmonella was isolated from the feces of
24 sows (21%) and antibodies to Salmonella LPS were detected
in the serum of 107 sows (95%). This indicates that although not
all are actively shedding Salmonella, 95% of sows had a previous
exposure to Salmonella spp. Therefore, our finding that a subset of
the piglets in this vaccine trial had maternally acquired antibodies
to Salmonella LPS is not surprising. Furthermore, since 95% of the
sows tested were Salmonella antibody positive, exposure of pigs to
Salmonella on-farm is probable, indicating a need for improved
interventions including vaccination.
Previous investigations have described potential DIVA vaccines
for swine utilizing different Salmonella gene targets (19–21). A
limitation of some currently licensed Salmonella vaccines is that
vaccination produces Salmonella antibodies in the host that can-
not be differentiated from antibodies produced during an active
infection, and therefore could interfere with surveillance programs
that monitor Salmonella in swine production facilities. To elim-
inate potential interference, a licensed vaccine (Salmoporc, IDT
Biologika GmbH) was modified (∆ompD) and a new ELISA was
developed to distinguish between infected and vaccinated animals
(19). The modified vaccine did not stimulate an immune response
that was detected in their anti-OmpD ELISA. However, current
surveillance programs (ongoing since the early 1990s) utilize a
Salmonella LPS ELISA, and switching to another ELISA method
would need further validation prior to implementation in swine
production. The use of S. Typhimurium LPS mutants for DIVA
vaccine development has also been explored (20). Specifically, S.
Typhimurium ∆rfaJ and ∆rfaL mutants when inoculated into
swine did not stimulate an anti-Salmonella LPS response in con-
trast to the parental wild-type S. Typhimurium. However, further
experiments in pigs were not performed utilizing these specific S.
Typhimurium (∆rfaJ and ∆rfaL) mutants, although the Salmo-
porc vaccine strain (above) was modified to incorporate the∆rfaJ
mutation (21). Inoculation of pigs with the Salmoporc-∆rfaJ
strain did not induce Salmonella-specific antibodies to LPS when
serum was analyzed using the IDEXX HerdChek Swine Salmo-
nella Test. In a S. Typhimurium transmission experiment whereby
vaccinated (Salmoporc-∆rfaJ ), non-challenged pigs were exposed
to S. Typhimurium-challenged “seeder” pigs, vaccination did not
significantly decrease the adjusted transmission ratio compared
to non-vaccinated pigs. As we performed a challenge experiment
and not a transmission experiment in this study, we cannot directly
compare our results to those of De Ridder et al.
Investigations in BALB/c mice have previously demonstrated
that a S. Typhimurium SL1344 rfaH mutant is attenuated and
protective against challenge with wild-type S. Typhimurium
SL1344 (8). Mutations in rfaH have also been constructed in
S. Typhimurium UK-1 and S. Gallinarum 287/91, and virulence
attenuation has been demonstrated for both of these rfaH mutants
in BALB/c mice and Rhode Island Red chicks, respectively (9,
22). Furthermore, inoculation of Rhode Island Red chickens with
two doses of the S. Gallinarum 287/91 rfaH mutant (χ11571)
provided significant protection against challenge with S. Galli-
narum χ4173. However, due to concerns by these investigators
that rfaH mutants may not adequately stimulate a robust immune
response (due to potentially poor colonization of the intestinal
tract and reduced invasion of epithelial cells in the intestine),
strains of S. Typhimurium UK-1 and S. Gallinarum 287/91 were
also constructed with rfaH expression under the control of the
arabinose promoter (PBAD), resulting in regulated delayed expres-
sion of rfaH (9, 22). The S. Typhimurium UK-1∆PrfaH178 mutant
(χ9735) with regulated delayed expression of rfaH was atten-
uated ~100-fold compared to wild-type S. Typhimurium UK-1
but was not as attenuated as the rfaH knockout mutant (χ9445
∆rfaH49) at >10,000-fold. In three-day old Rhode Island Red
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chicks, the S. Gallinarum 287/91 strain χ11386 (∆PrfaH178) with
regulated delayed expression of rfaH retained full virulence com-
pared to the wild-type S. Gallinarum 287/91 parent. In contrast,
the S. Gallinarum rfaH knockout mutant (χ11571) was atten-
uated ~1,000-fold. Although the mouse and chick experiments
were performed with two different Salmonella serovars, the results
using the regulated delayed expression of rfaH may highlight dif-
ferences between animal models that may impact the efficiency
of this delivery method. Clearly, the expression of rfaH following
arabinose induction does not wane quick enough to attenuate the
virulence of S. Gallinarum χ11386 (∆PrfaH178) in Rhode Island
Red chicks. Results from the S. Gallinarum rfaH (χ11571) vac-
cine trial in Rhode Island Red chickens and our S. Typhimurium
rfaH vaccine trial in swine indicate that the initial concern that
rfaH knockout mutants may be excessively attenuated and there-
fore not stimulate a sufficient immune response to provide pro-
tection against challenge may be unwarranted. Colonization of
swine intestinal tissues at 7 dpi with the BBS 202 (rfaH ) strain
indicates that the strain is present in multiple pigs for immune
stimulation.
Although the results of the vaccination trial presented in this
study are encouraging, additional investigations may be proposed
to further evaluate the use of an rfaH mutant as a potential
vaccine candidate in swine. For example, in our pig trials, we typ-
ically euthanize the animals at 7 days post-challenge in order to
quantitatively evaluate tissue colonization by Salmonella (after 7
d.p.i., quantitation in tissues steadily decreases resulting in only a
qualitative assessment (±), especially with a 108 inoculum). There-
fore, persistence of the rfaH mutant or of the challenge strain in
the vaccinated vs. mock-vaccinated pigs over an extended period
of time was not determined. Other parameters to be evaluated
in future studies include inoculation route, inoculum dose, and
age for vaccination (based on efficacy and industry practices),
vaccination protection against Salmonella transmission from a
Salmonella-shedding pig to a naïve pig, as well as evaluation of
the vaccine in a larger population of pigs. Despite the need for
further investigation, this initial evaluation of an rfaH mutant in
swine as a potential vaccine candidate addressed three objectives:
attenuation, protection, and interference with Salmonella surveil-
lance. Vaccination of swine with the attenuated S. Typhimurium
rfaH vaccine strain (BBS 202) reduced S. Typhimurium intesti-
nal colonization and fecal shedding but did not stimulate an
anti-Salmonella LPS immune response that would compromise
Salmonella surveillance programs for swine herds. Thus, vaccina-
tion with the S. Typhimurium rfaH vaccine strain permits the
DIVA.
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